PURPOSE: To retrospectively evaluate the prevalence of focal fluorodeoxyglucose (FDG) uptake by the thyroid gland on combined positron emission tomographic (PET) and computed tomographic (CT) scans in patients undergoing staging of newly diagnosed non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Institutional review board approval was obtained, informed consent was waived, and the study was Health Insurance Portability and Accountability Act-compliant. Whole-body PET/CT scans and medical records of 140 consecutive patients with newly diagnosed NSCLC (80 men, 60 women; mean age, 66 years; range, 39-89 years) were retrospectively reviewed by two experienced PET/CT scan readers. Maximum standardized uptake value (SUV) was calculated for FDG-avid thyroid foci. Corresponding thyroid CT findings were recorded in patients with focal increased FDG thyroid uptake. RESULTS: PET results showed that six patients (4.3%) had seven foci of increased FDG uptake in the thyroid. Five of the seven foci (in four patients) corresponded to a low-attenuation thyroid lesion on the nonenhanced CT scan. Lesions ranged in diameter from 0.8 to 2.5 cm. Four of the lesions were found to be papillary thyroid cancers at fine-needle aspiration biopsy. The fifth lesion was found to be benign at thyroidectomy. The remaining two patients did not have histologic confirmation of their thyroid lesion because no specific biopsy site was visualized on CT or sonographic images and lesions were considered benign. Maximum SUV of the thyroid cancers ranged from 3.0 to 32.9 (mean, 13.7). Maximum SUV of benign thyroid lesions ranged from 4.6 to 6.2 (mean, 5.4). CONCLUSION: Focal thyroid FDG uptake found during the initial staging of NSCLC at PET/CT indicates a high likelihood of primary thyroid cancer.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Jul 2005|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging